An investigational HIV vaccine tested in the “Imbokodo” clinical trial conducted in sub-Saharan Africa did not provide sufficient protection against HIV infection, according to a primary analysis of the study data. It posed no safety concerns. The Phase IIb proof-of-concept study, which began in November 2017, enrolled 2,637 women… Read More
ILC Therapeutics has completed a £3.5 million pre-IPO funding round. Investors include Robert Kopple, Eos Angel Investment Syndicate, Scottish Enterprise and ILCT management. Chairman Peter Bains said: “With this funding in place, ILCT is now well positioned to strengthen its novel technology platform and to advance its lead candidate, Alfacyte… Read More
Moderna has submitted a conditional marketing approval (CMA) with the European Medicines Agency (EMA) for the evaluation of a booster dose of the Moderna Covid-19 vaccine (mRNA-1273) at the 50 µg dose level. “We are pleased to submit for a conditional marketing approval with the EMA for our booster candidate at the 50… Read More
New data from the Navigator Phase III trial showed that AstraZeneca and Amgen’s tezepelumab reduced exacerbations and improved lung function and nasal symptoms in patients with severe, uncontrolled asthma and comorbid nasal polyps.1 Tezepelumab is a potential first-in-class treatment that acts by targeting thymic stromal lymphopoietin (TSLP), an… Read More
BIAL has entered into an agreement with Sunovion Pharmaceuticals whereby BIAL received exclusive commercial license rights to commercialise apomorphine sublingual film in the European Union (EU), the European Economic Area (EEA) and the United Kingdom. Apomorphine sublingual film (APL-130277) is a novel thin film formulation of apomorphine that dissolves… Read More
Newron Pharmaceuticals has initiated Study 008A, the first potentially pivotal study with evenamide in patients with schizophrenia. Results from the study are expected by the fourth quarter of 2022. Study 008A, a four-week, randomised, double-blind placebo-controlled international study, is designed to evaluate the efficacy, tolerability, and safety (including effects on the… Read More
News round-up by DDW’s Megan Thomas for 30 August – 3 September DDW’s Megan Thomas has rounded up five stories in which studies, collaborations and trials pave the way towards treatments for a number of potentially fatal conditions. 1. NIH studies Covid-19 vaccine dose for… Read More
Moderna has initiated its submission to the US Food and Drug Administration (FDA) for the evaluation of a booster dose of the Moderna Covid-19 vaccine (mRNA-1273) at the 50 µg dose level. The company expects to submit data to the European Medicines Agency (EMA) and other regulatory authorities around the world… Read More
This event provided expert insight from Dr. Richard L. Easton, Technical Director of Structural Analysis at BioPharmaSpec. He provides data from studies with monoclonal antibodies, heavily glycosylated species and PEGylated species showing how the Maurice platform can be used to provide reliable insights into the structure of different types of… Read More
Using an automated CE-SDS platform in efficient biosimilar comparability studies is a free-to-attend webinar which will be hosted by DDW and supported by Bio-Techne on 29 September at 4PM BST. Watch on Demand here. Join Dr Richard L Easton, Technical Director of Structural Analysis at BioPharmSpec as he discusses… Read More
Avacta has appointed Dr Fiona McLaughlin as Chief Scientific Officer of its therapeutics division, effective immediately. Dr McLaughlin is an experienced oncology drug developer, bringing over 25 years’ experience in research and translational drug development in the pharmaceutical and biotech sectors, having led teams from early research through to clinical… Read More
Sciex has launched a capillary electrophoresis solution, the BioPhase 8800 system. The multi-capillary system for CE-SDS processes eight samples simultaneously, retaining sample integrity and delivering consistent results. The development of biopharmaceutical therapies requires the ability to measure and monitor critical quality attributes in short timelines. The BioPhase 8800… Read More
Scientists from the University of Manchester have found that the drug Viagra, used to treat sexual impotence, can strongly suppress abnormal heart rhythms known as arrythmias in sheep. The British Heart Foundation funded study, published in Circulation Research, could have important implications on the management of the… Read More
Novartis and NHS England are to pioneer a population health management approach to address elevated LDL-C in patients with Atherosclerotic Cardiovascular Disease (ASCVD) across England. The collaboration received positive final recommendation from the National Institute for Health and Care Excellence (NICE) for use of inclisiran in primary care for the treatment of adult patients within its licenced indication1 who… Read More
Following the news that ELRIG’s Drug Discovery 2021 to host SLAS’s Innovation AveNEW, SLAS is accepting applications from startup and emerging technology companies for ten spots in the exhibition area being offered at ELRIG UK Drug Discovery 2021, October 19-20 in Liverpool. Accepted companies will be announced in early October. Read More
As previously reported by DDW, Avacta Group has dosed the first patient in its Phase I multicentre trial evaluating AVA6000, a novel pro-drug of Doxorubicin and the company’s first therapeutic based on its pre|CISION technology. Megan Thomas speaks Dr Alastair Smith, Chief Executive Officer of Avacta Group, about this development. MT: You previously commented that this study marks the… Read More
